Soleno Therapeutics, Inc.
SLNO
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company waā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$49.55
Price-0.44%
-$0.22
1Y
Price
Market Cap
$2.661b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+42.3%
EBITDA Margin+39.4%
Net Profit Margin+66.1%
Free Cash Flow MarginRevenue
$98.675m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$78.450m
+55.4%
1y CAGR-119.2%
3y CAGR-83.9%
5y CAGREPS
-$1.84
+58.0%
1y CAGR-3.3%
3y CAGR+10.2%
5y CAGRBook Value
$494.805m
$599.895m
Assets$105.090m
Liabilities$2.809m
DebtDebt to Assets
0.5%
-
Debt to EBITDAFree Cash Flow
-$25.742m
+62.9%
1y CAGR-45.0%
3y CAGR-27.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company